Jagran Correspondent, Haridwar. The results of clinical trials on Kovid-19 patients of Patanjali Ayurveda medicine ‘Divya Coronil Tablet’ will be announced at 12 noon today by Yoga Guru Baba Ramdev and Acharya Balakrishna at Patanjali Yogpeeth Phase-II. Patanjali Yogpeeth has stated that this research done on the corona tablet is the result of joint efforts of Patanjali Research Institute Haridwar and National Institute of Medical Science Jaipur. The tablet is being manufactured at Divya Pharmacy and Patanjali Ayurved Limited Haridwar. During this time, teams of scientists, researchers and doctors will also be present.
On 13 June last, Acharya Balakrishna, General Secretary of Patanjali Yogpeeth and Vice Chancellor of Patanjali Ayurvedic University, claimed in a conversation with ‘Dainik Jagran’ that after five months of research at Patanjali Research Institute and after several rounds of successful trials on mice, Kovid-19 Has been successful in preparing Ayurvedic medicine. The clinical case study required for this has been completed, while the clinical control trial is in its final stages. As soon as its data is available, the final analysis will be done and put into the drug market.
What is involved in medicine
According to Acharya Balakrishna, the main components of the medicine are Ashwagandha, Giloy, Tulsi, Shwassari juice and atomic oil. Their mixture and proportion have been decided according to research. He had also claimed that this drug is authentic from all major institutions, journals, etc., nationally and internationally, on the basis of its use, treatment and effect. This research has also been published in the International Journal of Biomedicine Pharmacotherapy of America.
This is how medicine works
Acharya Balakrishna said that Ashwagandha does not allow Kovid-19’s RBD to meet the ACE of the human body. This prevents the Kovid-19 virus from entering the healthy cells of the infected human body. Giloy also acts like Ashwagandha. This prevents infection from occurring. Tulsi’s compound not only inhibits the rate of increase in its coefficient by attacking the RNA-polymerases of Kovid-19, but also consumes it continuously. Respiratory juice prevents the formation of thick mucus and reduces inflammation of the lungs by eliminating mucus. Similarly, atomic oil can be used as a nasal drop.
300 researchers involved in research
Acharya Balakrishna said that the discovery of Kovid-19 drug ‘Divya Coronil Tablet’ was launched in China in December 2019 after reports of its infection steadily increasing. Its case study was done first and from January 2020, research was started for its drug discovery regarding the behavior and effects of the virus. About 300 research scholars of Patanjali Yogpeeth Research Center took part in this work. Reported that the drug has been approved by the ‘Clinical Trial Registry of India’. It will be available in the market from Tuesday. Along with this, there will also be Shasari Vati tablets.
